Abstract
We describe a 'one-stop' cholesterol clinic implementing a regime based on the Scandinavian Simvastatin Survival Study (4S) in patients with established coronary heart disease in a district general hospital. The clinic has been established in collaboration with the cardiac rehabilitation centre. It was commissioned as an audit project by the purchasing authority, Walsall Health, a need having been shown in a previous audit. In the new clinic, audit is inbuilt, rather than being carried out as a separate retrospective exercise, and undertaken prospectively for all patients. Central to this is a database, used for routine correspondence and administration, as well as monitoring outcome. This application of information technology has improved clinical practice. Attendance at the clinic has been excellent. Half the consultations have resulted in therapeutic interventions, many of which may otherwise have been missed. Over 50% of patients were eligible for lipid-lowering medication under the protocol. Cholesterol targets based on 4S were achieved but with much lower drug doses, which may have major cost implications. Cholesterol levels measured within 24 hours of admission for myocardial infarction were poor predictors of results obtained after convalescence. After the clinic visit, most patients were taking aspirin plus one or two other secondary prevention treatments. Guidelines have been issued to primary care. Future plans for audit links with general practitioners, integration of the metabolic and cardiological assessment of survivors of myocardial infarction, and for long-term monitoring of clinical events in treated patients are discussed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Channer K. S. Choosing drugs for secondary prevention after myocardial infarction: a pragmatic approach. Postgrad Med J. 1995 Jun;71(836):321–322. doi: 10.1136/pgmj.71.836.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goldbourt U., Behar S., Reicher-Reiss H., Agmon J., Kaplinsky E., Graff E., Kishon Y., Caspi A., Weisbort J., Mandelzweig L. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol. 1993 Apr 15;71(11):909–915. doi: 10.1016/0002-9149(93)90905-r. [DOI] [PubMed] [Google Scholar]
- Gould A. L., Rossouw J. E., Santanello N. C., Heyse J. F., Furberg C. D. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation. 1995 Apr 15;91(8):2274–2282. doi: 10.1161/01.cir.91.8.2274. [DOI] [PubMed] [Google Scholar]
- Jönsson B., Johannesson M., Kjekshus J., Olsson A. G., Pedersen T. R., Wedel H. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) Eur Heart J. 1996 Jul;17(7):1001–1007. doi: 10.1093/oxfordjournals.eurheartj.a014994. [DOI] [PubMed] [Google Scholar]
- Keech A., Collins R., MacMahon S., Armitage J., Lawson A., Wallendszus K., Fatemian M., Kearney E., Lyon V., Mindell J. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J. 1994 Feb;15(2):255–269. doi: 10.1093/oxfordjournals.eurheartj.a060485. [DOI] [PubMed] [Google Scholar]
- Oliver M., Poole-Wilson P., Shepherd J., Tikkanen M. J. Lower patients' cholesterol now. BMJ. 1995 May 20;310(6990):1280–1281. doi: 10.1136/bmj.310.6990.1280. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ryder R. E., Hayes T. M., Mulligan I. P., Kingswood J. C., Williams S., Owens D. R. How soon after myocardial infarction should plasma lipid values be assessed? Br Med J (Clin Res Ed) 1984 Dec 15;289(6459):1651–1653. doi: 10.1136/bmj.289.6459.1651. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301–1307. doi: 10.1056/NEJM199511163332001. [DOI] [PubMed] [Google Scholar]
- Smith G. D., Pekkanen J. Scandinavian simvastatin study (4S) Lancet. 1994 Dec 24;344(8939-8940):1766–1768. [PubMed] [Google Scholar]
- Smith J., Channer K. S. Increasing prescription of drugs for secondary prevention after myocardial infarction. BMJ. 1995 Oct 7;311(7010):917–918. doi: 10.1136/bmj.311.7010.917. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Smith R. The scientific basis of health services. BMJ. 1995 Oct 14;311(7011):961–962. doi: 10.1136/bmj.311.7011.961. [DOI] [PMC free article] [PubMed] [Google Scholar]